Can a sponsor block publication of university research? What universities accept, and what the model clauses say
Andrew T. Flowers ·
No. A company that funds research at a US university can't stop the results from being published, and the agreement you're offered will say so in one form or another. What a sponsor can get is time: a window to read the manuscript before it's submitted, the right to have its own confidential information taken out, and a short further delay if a patent has to be filed first. This article sets out what institutions actually accept, what the published model clauses say in their own words, and what the evidence shows about the alternative, so the clause you ask for is one the university can sign. The faculty version of the question, "will I still be allowed to publish?", is answered in the box halfway down.
We're not a law firm, and this isn't legal advice.
What review rights will a university accept, and for how long?
The best evidence comes from Mello, Clarridge, and Studdert's survey of the administrators who negotiate industry agreements at 107 of the 122 US medical schools (NEJM, 2005). Virtually all of them, 96%, said their office would accept a provision letting the sponsor review manuscripts for a limited time before publication. The consensus runs the other way on control: 89% called a provision letting the sponsor revise a manuscript impermissible, and 93% said the same of a provision letting the sponsor decide whether results are published. Asked the longest review period they'd allow, 14% said 30 days, 44% said 60, 31% said 90, and only 7% would go beyond 90. The pattern hasn't changed in the twenty years since: review yes, veto no, and the clock runs in weeks.
The same survey explains why institutions hold the line. Among the provisions administrators rated "very difficult" to negotiate for multicenter trials, intellectual property (31%) and data ownership (25%) led the list, and publication control sits downstream of both. An earlier survey by Schulman and colleagues of 108 medical schools had found that a median of only 1% of site agreements complied with the journal editors' standard that authors have access to all the trial data (NEJM, 2002), which is why data-access and publication clauses have tightened together.
Clinical trials are the hardest case, because the sponsor's product is on the line. In Kasenda and colleagues' review of 647 randomized-trial protocols, 456 (70.5%) mentioned a publication agreement, and 86.2% of those gave the sponsor review or disapproval rights (PLoS Medicine, 2016). Sponsored engineering or materials research rarely carries that kind of clause, and a university will push back harder on it when it does.
What do the model publication clauses say?
Three published frameworks carry the review-and-delay structure, and it's worth reading their words rather than a summary, because sponsors often ask for a number that none of them contains.
| Framework | Notice before submission | Sponsor's window to object | Delay for a patent filing | Veto |
|---|---|---|---|---|
| UIDP Contract Accord 3 (US sponsored research) | A "limited time period that is reasonable under the circumstance of the project and does not restrict publication through inaction" | Same window | A "limited delay of publication to protect potentially patentable IP," and "publication delays should not jeopardize academic progress of students" | No. The sponsor may have its confidential information deleted or modified. Trade-secret designation of results "is generally incompatible with the University's publication objective" |
| Lambert Model Collaboration Agreement 1 (UK), clause 5 | "At least [30][60] OR [90] days before the date of the proposed submission" (the parties pick) | "[15] OR [30] days" to give a confidentiality notice | "A maximum of [insert period] month(s)" to seek patent protection (a blank the parties fill) | No. The sponsor may prevent publication only of its own confidential background that can't be patented |
| DESCA 2.1 (EU consortia), section 8.4 | 45 calendar days in the DESCA-based agreements we checked | 30 calendar days, on stated grounds (protection of results or background, legitimate interests, confidential information) | Through the objection, not a separate clause | No. An objection must cite one of the listed grounds |
| NIH Public Access Policy (any NIH-funded work, from 1 July 2025) | Not a review clause. Author manuscripts go to PubMed Central on acceptance, available "without embargo" on publication | n/a | n/a | n/a. A sponsor can't contract around a federal funder's policy |
Two things stand out. First, the UIDP Accord deliberately gives no number. It asks for a review period that's reasonable for the project and that can't be used to stall by silence, which is the clause a sponsor should expect from a US university: 30 days is the common offer, 60 is the ceiling most institutions will accept, and the Mello figures show where the line is. Second, the only "block" any framework allows is over the sponsor's own confidential background, never over the results. If your draft says "approval," change the word to "review" and keep the window. The university will read "approval" as a veto and send it back.
The delay for a patent filing is the clause sponsors underuse. Both the Accord and Lambert allow one, and it's the legitimate reason to hold a paper: a public disclosure before filing destroys patent rights in most of the world outside the US grace period. Ask for 60 to 90 days, tied to a filing decision, with a dissertation carve-out so a student's defense isn't held for it.
Translation Box: "Will I still be allowed to publish?"
On the academic side: yes. No US research university will sign away your right to publish or your student's right to defend. What you'll agree to is a notice period and a short wait while the sponsor checks for its confidential information and decides about a patent. The clause to watch for is one that lets the sponsor "approve" rather than "review," or one with no end date. Ask the sponsored programs office to show you the publication clause before you agree to the project, and make sure the thesis is carved out.
On the industry side: the publication clause isn't where you protect your competitive position. The NDA, the background schedule, and the field-of-use license are. Treat the review window as a confidentiality check and a patent-timing device, and the university will treat you as a partner who has done this before.
Why won't a university give a sponsor a veto?
The reason universities refuse isn't abstract. The research record on sponsor control is consistent, and it comes mainly from medicine, where the stakes are highest and the data is best.
Blumenthal and colleagues surveyed 2,167 life-science faculty at the 50 universities receiving the most NIH funding and found that 19.8% had delayed publication by more than six months at least once in three years, for reasons that included patent applications and disputes over IP ownership, and that 8.9% had refused to share results with other university scientists. Participation in an industry research relationship was significantly associated with the delays (JAMA, 1997). Bekelman, Li, and Gross pooled eight studies covering 1,140 original studies and found industry sponsorship associated with pro-industry conclusions (pooled odds ratio 3.60) and "also associated with restrictions on publication and data sharing" (JAMA, 2003). Bourgeois, Murthy, and Mandl followed 546 registered drug trials: 32.4% of industry-funded trials were published within 24 months of completion, against 56.2% of trials funded by nonprofits without industry money, and industry-funded publications reported positive outcomes 85.4% of the time against 50.0% for government-funded trials (Annals of Internal Medicine, 2010). The Cochrane review by Lundh and colleagues puts the pooled effect at a 27% higher likelihood of favorable efficacy results and a 34% higher likelihood of favorable conclusions in industry-sponsored studies (Cochrane, 2017).
None of this says industry-sponsored research is bad science. Rasmussen and colleagues' study of 200 industry-funded trials found the funder involved in design in 92% of trials and in reporting in 87%, and most of the lead academic authors who answered their survey described the collaboration as beneficial. Only 3 of 80 reported a publication delay caused by the funder (BMJ, 2018). The lesson a sponsor should take is narrower: the record on control is why the clause is written the way it is, and a sponsor who asks for review rather than control is asking for the version the evidence supports.
There's one more reason, and it's the one that moves export-sensitive sponsors. Research done in the open, with no restriction on publication, is fundamental research and sits outside export-control licensing (15 CFR 734.8). A publication veto can cost the project that exclusion, which means the university may have to treat it as controlled work, with everything that implies for who can be in the lab. Universities refuse publication control partly to keep their own research exportable.
What publication clause should a sponsor ask for?
A review window of 30 to 60 days before submission, with the sponsor's silence meaning consent. The right to have the sponsor's confidential information removed, defined by reference to the background schedule and the NDA rather than at the sponsor's discretion. A further delay of up to 60 to 90 days, only where the sponsor commits to file a patent, with the thesis carved out. A joint-publication right for the sponsor's own scientists where they contributed. And nothing that uses the word "approve." Those terms will get signed at any US research university, and they're the ones our Contract Red Flags Kit score green.
On our Helikon platform, a review window is a dated obligation, and a project on Helikon tracks it as a milestone with its due date and reminder emails, so the manuscript reaches the sponsor on time and the clock is visible to both sides. The sponsor's guide covers the rest of the agreement.
Sources
- Mello, M. M., Clarridge, B. R., and Studdert, D. M., 2005, Academic medical centers' standards for clinical-trial agreements with industry, New England Journal of Medicine 352(21), 2202-2210. https://doi.org/10.1056/NEJMsa044115
- Schulman, K. A., et al., 2002, A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors, New England Journal of Medicine 347(17), 1335-1341. https://doi.org/10.1056/NEJMsa020349
- Kasenda, B., et al., 2016, Agreements between industry and academia on publication rights: a retrospective study of protocols and publications of randomized clinical trials, PLoS Medicine 13(6), e1002046. https://doi.org/10.1371/journal.pmed.1002046
- Blumenthal, D., Campbell, E. G., Anderson, M. S., Causino, N., and Louis, K. S., 1997, Withholding research results in academic life science, JAMA 277(15), 1224-1228. https://doi.org/10.1001/jama.277.15.1224
- Bekelman, J. E., Li, Y., and Gross, C. P., 2003, Scope and impact of financial conflicts of interest in biomedical research: a systematic review, JAMA 289(4), 454-465. https://doi.org/10.1001/jama.289.4.454
- Bourgeois, F. T., Murthy, S., and Mandl, K. D., 2010, Outcome reporting among drug trials registered in ClinicalTrials.gov, Annals of Internal Medicine 153(3), 158-166. https://pmc.ncbi.nlm.nih.gov/articles/PMC3374868
- Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., and Bero, L., 2017, Industry sponsorship and research outcome, Cochrane Database of Systematic Reviews, MR000033. https://doi.org/10.1002/14651858.MR000033.pub3
- Rasmussen, K., Bero, L., Redberg, R., Gøtzsche, P. C., and Lundh, A., 2018, Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors, BMJ 363, k3654. https://doi.org/10.1136/bmj.k3654
- UIDP, 2020, Contract Accord 3, Publication. https://uidp.org/publication/contract-accord-3-publication/
- UK Intellectual Property Office, 2018, Lambert Toolkit, Model Collaboration Agreement 1, clause 5. https://assets.publishing.service.gov.uk/media/5b068545ed915d7615081007/Collaboration_Agreement_1__May_2018_.pdf
- DESCA, 2026, Horizon Europe Model Consortium Agreement, version 2.1, section 8.4 (the 45-day and 30-day periods are as they appear in the DESCA-based agreements we checked). https://www.desca-agreement.eu/
- National Institutes of Health, 2024 and 2025, NIH Public Access Policy, NOT-OD-25-047 and NOT-OD-25-101. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-101.html
- Export Administration Regulations, fundamental research, 15 CFR 734.8. https://www.ecfr.gov/current/title-15/subtitle-B/chapter-VII/subchapter-C/part-734/section-734.8